Evidence map›Paper›PMID 41424810›Full record

ArticleTransboundary and emerging diseases2025

Emergence of Mobilized Tigecycline Resistance Gene Cluster

Hanyun Wang, Yujing Zhang, Zhenyu Wang, Yawen Xu, Le Zhou, Jing Wang, Xinan Jiao, Lin Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Emergence of Mobilized Tigecycline Resistance Gene ClusterTransboundary and emerging diseases · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hanyun WangJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China, yzu.edu.cn.
Yujing ZhangJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China, yzu.edu.cn.
Zhenyu WangJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China, yzu.edu.cn.
Yawen XuDepartment of Clinical Laboratory, Yangzhou Center for Disease Control and Prevention, Yangzhou, China.
Le ZhouDepartment of Clinical Laboratory, Yangzhou Center for Disease Control and Prevention, Yangzhou, China.
Jing WangJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China, yzu.edu.cn.
Xinan JiaoJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China, yzu.edu.cn.
Lin SunJiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, China, yzu.edu.cn.ORCID https://orcid.org/0000-0002-5986-3260

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tigecycline is considered a last-line therapeutic option for treating infections caused by multidrug-resistant (MDR) Gram-negative bacteria. The emergence of

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialEnterobacteriaceaeEnterobacteriaceae InfectionsSwine DiseasesTigecyclineAnimalsChinaDrug Resistance, Multiple, BacterialFarmsMultigene FamilySwineVirulenceAnti-Bacterial AgentsTigecyclineIS26Raoultella ornithinolyticaswine farmtigecycline resistancetmexCD-toprJ

Identifiers

PMID41424810
PMCPMC12714096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.